China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more
China Shineway Pharmaceutical Group Limited (CSWYF) - Net Assets
Latest net assets as of June 2025: $7.81 Billion USD
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (CSWYF) has net assets worth $7.81 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.39 Billion) and total liabilities ($2.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.81 Billion |
| % of Total Assets | 75.18% |
| Annual Growth Rate | 27.64% |
| 5-Year Change | 714.07% |
| 10-Year Change | N/A |
| Growth Volatility | 204.53 |
China Shineway Pharmaceutical Group Limited - Net Assets Trend (2015–2024)
This chart illustrates how China Shineway Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for China Shineway Pharmaceutical Group Limited (2015–2024)
The table below shows the annual net assets of China Shineway Pharmaceutical Group Limited from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.47 Billion | +652.99% |
| 2023-12-31 | $991.63 Million | +8.10% |
| 2022-12-31 | $917.31 Million | -3.71% |
| 2021-12-31 | $952.62 Million | +3.86% |
| 2020-12-31 | $917.23 Million | +9.58% |
| 2019-12-31 | $837.07 Million | -0.32% |
| 2018-12-31 | $839.80 Million | -7.23% |
| 2017-12-31 | $905.23 Million | +9.68% |
| 2016-12-31 | $825.35 Million | -0.54% |
| 2015-12-31 | $829.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to China Shineway Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1053.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.73 Billion | 90.08% |
| Common Stock | $87.66 Million | 1.17% |
| Other Components | $652.81 Million | 8.74% |
| Total Equity | $7.47 Billion | 100.00% |
China Shineway Pharmaceutical Group Limited Competitors by Market Cap
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sam Engineering Equipment
KLSE:9822
|
$207.98 Million |
|
Television Broadcasts Ltd
PINK:TVBCY
|
$208.00 Million |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
$208.03 Million |
|
Suzhou Cheersson Precision Metal Fo
SHE:002976
|
$208.10 Million |
|
Zhejiang Dayang Biotech Group Co
SHE:003017
|
$207.86 Million |
|
EQUALS GROUP PLC LS-01
F:2FX
|
$207.83 Million |
|
Guangzhou Jointas Chemical Joint Stock Co Ltd
SHE:002909
|
$207.74 Million |
|
Contrel Technology Co Ltd
TWO:8064
|
$207.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Shineway Pharmaceutical Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 991,632,943 to 7,466,904,000, a change of 6,475,271,057 (653.0%).
- Net income of 840,052,000 contributed positively to equity growth.
- Dividend payments of 407,916,000 reduced retained earnings.
- Other comprehensive income increased equity by 69,724,562.
- Other factors increased equity by 5,973,410,495.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $840.05 Million | +11.25% |
| Dividends Paid | $407.92 Million | -5.46% |
| Other Comprehensive Income | $69.72 Million | +0.93% |
| Other Changes | $5.97 Billion | +80.0% |
| Total Change | $- | 652.99% |
Book Value vs Market Value Analysis
This analysis compares China Shineway Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.02x to 0.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.99 | $1.00 | x |
| 2016-12-31 | $0.98 | $1.00 | x |
| 2017-12-31 | $1.08 | $1.00 | x |
| 2018-12-31 | $1.03 | $1.00 | x |
| 2019-12-31 | $1.06 | $1.00 | x |
| 2020-12-31 | $1.17 | $1.00 | x |
| 2021-12-31 | $1.23 | $1.00 | x |
| 2022-12-31 | $1.21 | $1.00 | x |
| 2023-12-31 | $1.31 | $1.00 | x |
| 2024-12-31 | $9.88 | $1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Shineway Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.25%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.24%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.34x
- Recent ROE (11.25%) is above the historical average (10.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 12.84% | 32.02% | 0.35x | 1.16x | $23.15 Million |
| 2016 | 10.97% | 29.56% | 0.32x | 1.15x | $7.83 Million |
| 2017 | 7.45% | 23.52% | 0.28x | 1.15x | $-22.78 Million |
| 2018 | 9.11% | 19.68% | 0.40x | 1.17x | $-7.45 Million |
| 2019 | 8.83% | 18.59% | 0.38x | 1.23x | $-9.71 Million |
| 2020 | 4.83% | 11.11% | 0.35x | 1.24x | $-45.84 Million |
| 2021 | 9.29% | 17.27% | 0.44x | 1.22x | $-6.54 Million |
| 2022 | 11.73% | 18.30% | 0.50x | 1.29x | $15.86 Million |
| 2023 | 13.83% | 3.04% | 3.35x | 1.36x | $38.00 Million |
| 2024 | 11.25% | 22.24% | 0.38x | 1.34x | $93.36 Million |
Industry Comparison
This section compares China Shineway Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Shineway Pharmaceutical Group Limited (CSWYF) | $7.81 Billion | 12.84% | 0.33x | $207.87 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |